Notification Requirements for Schedule 3, WTO Member Countries

Countries that are members of the World Trade Organization (WTO), as listed on Schedule 3 to Canada's Patent Act, are required to notify the WTO of their plans to use Canada's Access to Medicines Regime (model notification letter). For instructions on how to provide notice, see Notifying the World Trade Organization.

Countries must disclose the following information to the WTO when planning to use the Regime:

• The name and quantity of the drug or medical device needed;
• A declaration that the importing country does not have the capacity to manufacture the needed product; and
• A declaration that the product is not patented in the importing country; or
• If the product is patented in the importing country, a declaration that the country will or has issued a compulsory licence authorizing the use of the product.

For a graphic illustration of the notification process, see the process map for Schedule 3 countries.